Position in MRK
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$644,813
+$203,590 QoQ
Shares Held
5,018
+36.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
#2,473
of 3,769 holders
Holding Since
Dec 2022
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Fortis Capital Advisors, LLC holds $12,414,388 across 8 Drug Manufacturers - General names. MRK ranks #5 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,684 | $4,418,700 | |
| 2 | ABBV |
AbbVie Inc.
|
16,124 | $4,057,443 | |
| 3 | JNJ |
Johnson & Johnson
|
4,470 | $1,135,245 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
13,795 | $794,867 | |
| 5 | MRK |
Merck & Co., Inc.
This page
|
5,018 | $644,813 | |
| 6 | PFE |
Pfizer Inc
|
21,511 | $517,984 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
3,369 | $425,639 | |
| 8 | AMGN |
Amgen Inc
|
1,159 | $419,697 |
All Filings in MRK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $644,813 | 5,018 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $441,223 | 3,668 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $200,520 | 1,905 | Shares | Sole | 2026-01-27 | |
| 2025-06-30 | $204,628 | 2,585 | Shares | Sole | 2025-07-21 | |
| 2025-03-31 | $241,454 | 2,690 | Shares | Sole | 2025-05-20 | |
| 2023-03-31 | $105,645 | 993 | Shares | Other | 2023-05-15 | |
| 2022-12-31 | $108,509 | 978 | Shares | Defined | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||